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1946Background: Excessive production of reactive oxygen species (ROS), in part via upregulation of DNA damage
pathways, is a central mechanism governing pathologic activation of vascular smooth muscle cells (VSMCs).
We hypothesized that the breast cancer 1, early onset (BRCA1) gene that is involved in cellular resistance to
DNA damage limits ROS production and oxidative stress in VSMCs.
Methods: We evaluated basal and H2O2-stimulated expression of BRCA1 in human aortic smooth
muscle cells (HASMCs). In vitro gain-of-function experiments were performed in BRCA1 adenovirus
(Ad-BRCA1)-transfected HASMCs. ROS production and expression of Nox1 and its key regulatory
subunit p47phox, key components of the ROS-generating nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase system, were evaluated. In vivo gain-of-function experiments were performed in
spontaneously hypertensive (SHR) rats treated with Ad-BRCA1 (5 3 1010 IU/rat). Blood pressure, vascular
ROS generation, Nox1, and p47phox expression were measured.
Results: BRCA1 was constitutively expressed in murine, rat, and human smooth muscle cells (SMCs). H2O2
significantly reduced BRCA1 expression with a resultant increase in ROS generation. BRCA1-overexpressing
HASMCs were protected against H2O2-induced ROS generation, in part, via downregulation of the
ROS-producing NADPH oxidase subunits Nox1 and p47phox. Ad-BRCA1 treatment in SHR rats was associated
with a sustained increase in aortic BRCA1 expression, lower aortic ROS production, reduced gH2A.X levels,
greater RAD51 foci, and decreases in blood pressure.
Conclusions: BRCA1 is a novel and previously unrecognized target that may shield VSMCs from oxidative
stress by inhibiting NADPHNox1-dependent ROS production. Gene- and/or cell-based approaches that improve
BRCA1 bioavailability may represent a new approach in the treatment of diverse vascular diseases associated
with an aberrant VSMC phenotype. (J Thorac Cardiovasc Surg 2014;147:1946-55)Supplemental material is available online.e Divisions of Cardiac Surgery,a Medicine & Hematology-Oncology,b Endo-
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The Journal of Thoracic and Cardiovascular SurVSMCs are responsible for arterial contractile tone and
regulating blood pressure and flow to meet metabolic
demands.1-4 In response to a variety of acquired risk factors,
and/or alterations in shear stress, VSMCs undergo
pathologic activation, with marked changes in structure
and function, which have been causally related to
several cardiovascular diseases, including hypertension,
atherosclerosis, neointimal hyperplasia/restenosis, and
aneurysm formation.1-7
One of the best described mechanisms of VSMC activa-
tion is oxidative stress, due mainly to increased production
of reactive oxygen species (ROS) such as superoxide, and/
or a reduced ability to quench ROS due to a diminished
bioavailability of nitric oxide (NO) or antioxidant
enzymes.1,2 ROS stimulate various signaling pathways
within the VSMC, including mitogen-activated protein
kinases (MAPK), tyrosine kinases, Rho kinase, and
transcription factors such as nuclear factor kappa B, acti-
vator protein-1, and hypoxia-inducible factor 1, in addition
to stimulating protooncogene and proinflammatory gene
expression. With progressive exposure to ROS and oxida-
tive stress, cells undergo irreversible DNA damage resultinggery c June 2014
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DHE ¼ dihydroethidium
DSB ¼ double-strand breaks
GAPDH ¼ glyceraldehyde-3-phosphate
dehydrogenase
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Sin apoptosis and/or necrosis.1,2 Therefore, identifying the
mechanisms of the deleterious effects of oxidative stress
can serve as a novel approach to limit VSMC activation,
and the associated pathologic consequences.
The breast cancer 1, early onset (BRCA1) gene functions
as a caretaker of genome stability and exerts multiple
effects on key cellular processes involved in DNA damage
repair, transcriptional regulation, ubiquitination, and cell
cycle control.8,9 Although BRCA1 is widely known as a
tumor suppressor gene in breast and ovarian cancer
syndromes, accumulating evidence suggests that BRCA1
and BRCA2 may function to limit oxidative stress–
induced DNA damage in other tissues, and through this
mechanism may afford protection against ischemic and
genotoxic cardiac failure, atherosclerosis, and sepsis.10-14
Because oxidative stress is an important trigger for DNA
damage, and BRCA1 is well described to limit oxidative
and genotoxic injury, we hypothesized that it may function
in a similar fashion within VSMCs, guarding them against
oxidative injury and ROS production. This study shows
that BRCA1 may serve to limit VMSC ROS production in
part through an nicotinamide adenine dinucleotide
phosphate (NADPH)–dependent pathway, and that in vivo
BRCA1 gene delivery reduces aortic oxidative stress and
blood pressure in hypertensive animals.FIGURE 1. BRCA1 is constitutively expressed in aortic SMCs.
A, Representative agarose gel image and (B) immunoblot confirming the
constitutive presenceofBRCA1 transcript and protein inC57Bl/6JMASMCs,
WKYRASMCs and HASMCs. n¼ 5 per group. SMC, Smooth muscle cells;
BRCA1, breast cancer 1, early onset gene; MW, molecular weight marker;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.METHODS
Reagents
Human aortic smooth muscle cells (HASMCs) from healthy donors
were purchased from Lonza (Walkmersville, Md) and cultured in medium
from Gibco (Carlsbad, Calif). Antibodies directed against glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), NADPH oxidase catalytic subunit
1 (Nox1), and p47phox were fromMillipore (Etobicoke, Ontario, Canada),
Cell Signaling Technology, Inc (Danvers, Mass), and Santa CruzThe Journal of Thoracic and CarBiotechnology (Santa Cruz, Calif), respectively. The custom-designed
BRCA1 adenovirus (Ad-BRCA1; containing the complete coding
sequence of human BRCA1 [accession no. NM_007294.2]) and the control
adenovirus Ad-null were from Vector BioLabs (Philadelphia, Penn).
Both were under the control of the cytomegalovirus promoter.
Reagents for standard and real-time polymerase chain reaction (qPCR)
were from Applied Biosystems (Burlington, Ontario, Canada) and Qiagen
(Toronto, Ontario, Canada). Immunoblotting reagents and 6-chloromethyl-
20,70-dichlorodihydrofluorescein diacetate, acetyl ester (CM-DCF) were
from Life Technologies (Burlington, Ontario, Canada). The remaining
reagents were from Sigma (Oakville, Ontario, Canada).
Animals
Male spontaneously hypertensive (SHR) and normotensive Wistar-
Kyoto (WKY) rats (6-8 weeks old) were from Charles River Laboratories
International, Inc (Wilmington, Mass). When necessary, rats were injected
with Ad-null or Ad-BRCA1 (5 3 1010 IU/rat) via their tail veins. Male
(8 weeks old) C57Bl/6J mice were from the Jackson Laboratory
(Bar Harbor, Me). All animal procedures were in accordance with the
guidelines of the Canadian Council on Animal Care and were approved
by the St. Michael’s Hospital Animal Care Committee.
Radiotelemetry Recordings
Radiotelemetric catheters (model PA-C10; Data Sciences International,
St. Paul, Minn) were implanted in the abdominal aorta of 6-week-old rats at
the Charles River Laboratories (Raleigh, NC). Rats were exported to St.
Michael’s Hospital a week later where they were allowed to acclimatize
for 7 days before they were administered either Ad-null or Ad-BRCA1
(5 3 1010 IU/rat) via the tail vein. Arterial pressure and heart rate
data were acquired for 1 minute every 6 hours by the Dataquest A.R.T.
4.10 software via RPC-1 receivers (Data Sciences International).
Isolation and Culture of Rat and Mouse Aortic
Smooth Muscle Cells
Rat and mouse aortic smooth muscle cells (RASMCs and MASMCs,
respectively) were isolated by enzymatic dispersion of whole aortas.diovascular Surgery c Volume 147, Number 6 1947
FIGURE 2. BRCA1 overexpression reduces oxidative stress in HASMCs via the NADPH oxidase system. ROS production was determined by
(A) CM-DCF and (B) DHE fluorescence in HASMCs stressed for 24 hours with H2O2. Representative Western blots and semiquantitative data for the
NADPH oxidase subunits (C) Nox1 and (D). p47phox in naive and adenovirus-treated HASMCs. GAPDH acted as the housekeeping protein. n ¼ 5 per
group. *P< .05 versus the corresponding untreated group; yP< .05 versus the H2O2-treated Ad-null–transfected group. CM-DCF, 6-Chloromethyl-
20,70-dichlorodihydrofluorescein diacetate, acetyl ester; Ad-null, control adenovirus; Ad-BRCA1, BRCA1 adenovirus; DHE, dihydroethidium;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.




SBriefly, aortas were opened longitudinally, the endothelial layer gently
scraped, and the media removed from the underlying adventitia into a
cocktail of collagenase (1 mg/mL), soybean trypsin inhibitor (1 mg/mL),
and elastase (0.744 U/mL) in Hanks balanced salt solution for 60 minutes
at 37C. RASMCs so isolated were cultured in Dulbecco’s modified Eagle
medium/Nutrient Mixture F-12 medium supplemented with 20% fetal
bovine serum and antibiotics. Studies were performed on SMCs from
passages 4 to 7. Subconfluent cell cultures were rendered quiescent by
serum deprivation 24 hours before initiation of all experiments.ROS Production
Generation of ROS was assessed in naive or adenovirus-transfected
HASMCs and RASMCs via CM-DCF and dihydroethidium (DHE) fluores-
cence. ROS signals were captured by confocal microscopy after SMCs had
been stimulated with H2O2 (100 mM) for 24 hours and incubated in the dark
for either 45 minutes with 10 mMCM-DCF or 30 minutes with 5 mMDHE.
Aortic ROS production was assessed by lucigenin-enhanced chemilu-
minescence. Briefly, freshly isolated aortic segments were incubated for
30 minutes at 37C in 95% O2/5% CO2–aerated modified Krebs-HEPES
buffer containing in mmol/L: NaCl 99.01, KCl 4.69, CaCl2 1.87, MgSO4
1.20, Na-HEPES 20.0, K2HPO4 1.03, NaHCO3 25.0, and D-(þ)-glucose1948 The Journal of Thoracic and Cardiovascular Sur11.1 (pH 7.4). Aortic segments were subsequently transferred to 24-well
plates; each well contained 2 mL of Krebs-HEPES buffer with 5 mmol/L
lucigenin. Luminescence for each aortic segment was recorded and
normalized to its dry weight.
NADPH Oxidase Activity
RASMCs were washed in ice-cold phosphate buffered saline and resus-
pended in a lysis buffer (pH 7.4) containing KH2PO4 (20 mmol/L),
ethylene glycol tetraacetic acid (EGTA; 1 mmol/L), and protease inhibi-
tors. NADPH (0.1 mmol/L) was added to 200 mL of suspensions containing
50 mL of RASMC or thoracic aorta homogenate, 5 mmol/L lucigenin, and
assay buffer (in mmol/L: KH2PO4 50, EGTA 1, sucrose 150; pH 7.4) before
chemiluminescence was recorded.
RNA Analyses
RNA extracted from whole tissues and intact SMCs were reverse
transcribed with a TaqMan reverse transcription kit before qPCR was
performed on the StepOnePlus Real-Time PCR System using the TaqMan
Universal PCR Mix. Gene expression data were analyzed by the DDCt
method. In some cases, RNA from intact SMCs and liver samples were
examined via traditional PCR methods.gery c June 2014
FIGURE3. Aortas and RASMCs fromSHR rats express less BRCA1 than
those from WKY rats. BRCA1 transcripts in (A) WKYand SHR rat aorta
and (B) RASMC homogenates were assessed via qPCR. n ¼ 5 per group.
*P<.05 versus WKY group. BRCA1, Breast cancer 1, early onset gene;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; WKY, Wistar-
Kyoto rat; SHR, spontaneously hypertensive rat; RASMC, rat aortic smooth
muscle cells.





Protein lysates were separated on 4% to 20% polyacrylamide gels and
transferred to nitrocellulose membranes, which were subsequently probed
with antibodies directed against Nox1, p47phox, and GAPDH and
incubated with the appropriate horseradish peroxidase-tagged secondary
antibody. Immunoblotting signals were revealed with chemiluminescence
and quantified by densitometry.
Transfection
HASMCs and RASMCs were incubated for 24 hours with 10
multiplicity of infection (MOI) of Ad-BRCA1 or Ad-null. Transfection
efficiency was evaluated by qPCR.
Histology
Whole aortas were snap frozen in optimal cutting temperature
compound and sectioned (5 mm) before being processed for routine
immunohistochemical examination. Sections were incubated with anti-
bodies directed against either gH2A.X (1:50; Thermo Scientific, Waltham,
Mass) or RAD51 (1:50; Millipore). Nuclei positive for gH2A.X or RAD51
were quantified in 5 random fields.The Journal of Thoracic and CarStatistics
Data are presented as means (standard error of the mean) and were
analyzed with either the Student t test or 1-way analysis of variance
followed by the Bonferroni multiple comparisons procedure for all
secondary t tests of means.RESULTS
BRCA1 Is Constitutively Expressed in SMCs
We confirmed that BRCA1 is constitutively expressed at
both the transcript and protein levels in aortic SMCs from
mice, rats, and humans (Figure 1).BRCA1 Guards SMCs Against Oxidative Stress
Increased oxidative stress is an essential mechanism
leading to SMC dysfunction in various cardiovascular
disease states. To evaluate the relationship between
BRCA1 and oxidative stress, HASMCs were treated with
the prototypical oxidant H2O2 and changes in BRCA1
expression were measured. BRCA1 expression was mark-
edly attenuated by H2O2 in a concentration-dependent
manner with an approximately 40% reduction in
BRCA1 expression noted at 100 mM H2O2 (Figure E1).
Accordingly, this concentration of H2O2 was used in the
subsequent experiments.
To elucidate whether BRCA1 protects SMCs from
oxidative stress, ROS production was measured in
BRCA1-overexpressing HASMCs exposed to H2O2 via
CM-DCF fluorescence and DHE staining (Figure 2, A and
B). The elaborated ROS production elicited by H2O2 was
completely inhibited in Ad-BRCA1–transfected HASMCs
(Figure 2, A). Superoxide generation, as assessed by DHE
staining, was also markedly lower in H2O2-stressed
BRCA1 overexpressing HASMCs relative to the corre-
sponding Ad-null-treated group (Figure 2, B).
ROS generation in SMCs is largely controlled by the
NADPH oxidase (Nox) system. Nox1 is found abundantly
in SMCs and requires the regulatory subunit p47phox for
its activity. We observed that, whereas H2O2 caused a
significant increase in Nox1 and p47phox expression in
Ad-null-treated HASMCs, this effect was attenuated in
Ad-BRCA1–transfected HASMCs (Figure 2, C and D).
These data suggest that in SMCs, BRCA1 serves to
attenuate H2O2-induced ROS production, in part, through
a Nox1-dependent pathway.SMCs From Hypertensive Animals Exhibit Reduced
BRCA1 Expression and Increased Susceptibility to
Oxidative Stress
Increased VSMC oxidative stress has been implicated as a
causal mechanism of hypertension in various animal models,
including the SHR rat. To extend our invitro observations, we
tested BRCA1 expression and ROS production in aortic
SMCs isolated from SHR and WKY control rats. We also
performed gain-of-function in vivo studies to determine ifdiovascular Surgery c Volume 147, Number 6 1949
FIGURE 4. BRCA1 overexpression reduces oxidative stress in SHR RASMCs via the NADPH oxidase system. A, ROS production and (B) NADPH oxidase
activity were assessed by CM-DCFfluorescence and lucigenin-enhanced chemiluminescence, respectively, in homogenates ofWKYRASMCs and adenovirus-
transfectedSHRRASMCs (n¼ 6per group).RepresentativeWesternblots and semiquantitative data for theNADPHoxidase subunits (C)Nox1 and (D) p47phox
inWKYand SHR RASMC homogenates. n¼ 5 per group. *P<.05 versusWKY group; yP<.05 versus Ad-null SHR group. CM-DCF, 6-Chloromethyl-20,70-
dichlorodihydrofluorescein diacetate, acetyl ester; WKY, Wistar-Kyoto rat; Ad-null, control adenovirus; Ad-BRCA1, BRCA1 adenovirus; SHR, spontaneously
hypertensive rat; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NADPH, nicotinamide adenine dinucleotide phosphate.




Ssystemic overexpression of BRCA1 would reduce SMC
oxidative stress and lower blood pressure in SHR rats.
Basal BRCA1 transcript levels, as measured by qPCR,
were significantly lower in aortas and RASMCs from
SHR rats compared with WKY rats (Figure 3), supporting
the notion that BRCA1 may play a fundamental role in
the spontaneous development of hypertension in SHR rats.
An 18-fold difference in BRCA1 expression was
observed between Ad-BRCA1–transfected SHR RASMCs
and Ad-null-transfected SHR RASMCs, thus confirming
successful transfection (Figure E2). CM-DCF fluorescence
measurements indicated that the ROS levels in naive
RASMCs from SHR rats were markedly higher than those
in naive RASMCs fromWKY rats (Figure 4, A). ROS levels
in BRCA1-overexpressing SHR RASMCs were appre-
ciably lower than those in naive and Ad-null–transfected
SHR RASMCs (Figure 4, A).1950 The Journal of Thoracic and Cardiovascular SurWe then investigated the role of NADPH oxidase in
modulating the protective effects of BRCA1 to limit ROS
production in RASMCs from SHR rats. NADPH oxidase
activity was significantly higher in naive RASMCs from
SHR rats compared with WKY rats and, importantly,
BRCA1 overexpression attenuated the enhanced NADPH
activity noted in SHR RASMCs (Figure 4, B). Correspond-
ingly, Nox1 and p47phox protein levels, highest in
naive and Ad-null–transfected SHR RASMCs, were
markedly lower in BRCA1-overexpressing SHR RASMCs
(Figure 4, C and D).
In Vivo BRCA1 Gene Delivery Attenuates Vascular
Oxidative Stress and Lowers Blood Pressure in
Hypertensive Animals
Because vascular oxidative stress plays an important role
in the development of hypertension, we hypothesized thatgery c June 2014
FIGURE 5. BRCA1 overexpression lowers systolic and diastolic
blood pressure in SHR rats. A, Blood pressure and (B) heart rates were
continuously recorded via radiotelemetry in SHR rats treated with either
Ad-null or Ad-BRCA1 (5 3 1010 IU/rat, intravenously). n ¼ 9 per group.
*P < .05 versus Ad-null. Ad-null, Control adenovirus; Ad-BRCA1,
BRCA1 adenovirus.




Ssystemic BRCA1 gene therapy would lower aortic ROS
production and in turn attenuate blood pressure in SHR
rats. The adequacy of adenovirus delivery was confirmed
by demonstrating that BRCA1 expression was higher in
livers harvested from SHR rats 1 week after Ad-BRCA1
or Ad-null administration (Figure E3, A) and that 4 weeks
after adenovirus administration, aortic BRCA1 transcript
levels were markedly higher in SHR rats treated with
Ad-BRCA1 compared with Ad-null (Figure E3, B).
Ad-BRCA1 therapy resulted in an early and sustained
reduction in both systolic and diastolic blood pressure
without any effect on heart rate (Figure 5). The average
systolic and diastolic blood pressure was appreciably lower
in animals injected with Ad-BRCA1 compared with Ad-
null (systolic: Ad-null, 180.6  4.8 mm Hg; Ad-BRCA1,
169.2  3.8 mm Hg, P<.05; diastolic: Ad-null, 130.5 
4.9 mm Hg; Ad-BRCA1, 119.3  3.3 mm Hg, P<.05).The Journal of Thoracic and CarROS production, as evaluated by lucigenin-enhanced
chemiluminescence, was appreciably lower in aortas from
SHR rats treated with Ad-BRCA1 compared with Ad-null
(Figure 6, A). Aorta homogenates from SHR rats treated
with Ad-BRCA1 (vs Ad-null) demonstrated lower NADPH
oxidase activity (Figure 6, B) and revealed less Nox1 and
p47phox protein (Figure 6, C). Levels of gH2A.X, an end
point of ROS-associated double-strand breaks (DSBs),
was higher in the SMC nuclei of aortas from SHR rats
than in those from WKY rats (Figure 7). The enhanced
gH2A.X levels were notably absent in aortic samples
from SHR rats that had previously received BRCA1 gene
therapy (Figure 7). Furthermore, RAD51 foci formation,
an indicator of DNA repair, was significantly lower in
SMCs from SHR rat aortas than in SMCs from WKY rat
and Ad-BRCA1–treated SHR rat aortas (Figure 8).
DISCUSSION
The present study identifies a previously unrecognized
role of BRCA1 as a potential target to shield VSMCs
from oxidative stress in vitro and in vivo. This study
demonstrates that (1) BRCA1 is basally expressed in
rat, murine, and human VSMCs; (2) prooxidants such
as H2O2 reduce BRCA1 expression in VSMCs;
(3) in vitro gain-of-function strategies with Ad-BRCA1
overexpression reduce H2O2-induced ROS production via
a downregulation of Nox1 and its regulatory subunit
p47phox; (4) VSMCs isolated from hypertensive SHR
rats exhibit an increase in NADPH oxidase activity and
ROS generation, which is attenuated by in vivo gene
therapy with Ad-BRCA1; and (5) in vivo gene therapy
with Ad-BRCA1 causes a reduction in blood
pressure in SHR rats. In addition to extending our
current understanding of BRCA1-mediated cellular
protection,10-14 these data provide a translational link
between ROS, DNA repair genes, and aberrant VSMC
regulation.
ROS have been implicated as a central mechanism
through which VSMCs undergo pathologic cellular
activation resulting in aberrant phenotypic modulation,
differentiation, migration, proliferation, extracellular ma-
trix production, and cytoskeletal rearrangement. These
pathologic changes in VSMCs have been causally linked
to the development of various vascular diseases, including
atherosclerosis, restenosis, neointimal hyperplasia, and
aneurysm formation.1-7
NADPH oxidases are an important source of vascular
ROS.1,2 The NADPH oxidase family comprises 7 Nox
isoforms (Nox1-5, Duox 1, and Duox2), which function
primarily as ROS-generating enzymes, leading to the
production of superoxide and other free radicals. The Nox
family represents transmembrane-associated proteins that
transfer electrons across membranes such that the final
electron acceptor is O2 and superoxide is generated.diovascular Surgery c Volume 147, Number 6 1951
FIGURE 6. BRCA1 overexpression reduces aortic oxidative stress in SHR rats via the NADPH oxidase system. A, ROS production (n¼ 10 per group) and
(B)NADPHoxidase activity (n¼ 6 per group) in aorta homogenates fromWKYand adenovirus-treated SHR ratswere assessed by lucigenin-enhanced chem-
iluminescence. C, Representative Western blots and semiquantitative data for the NADPH oxidase subunits Nox1 and p47phox in WKY and adenovirus-
treated SHR rat aortas. GAPDH acted as the housekeeping protein. n ¼ 6 per group. *P<.05 versus WKY group; yP<.05 versus Ad-null SHR group.
ROS, Reactive oxygen species; WKY, Wistar-Kyoto rat; Ad-null, control adenovirus; Ad-BRCA1, BRCA1 adenovirus; SHR, spontaneously hypertensive
rat; RLU, relative light units; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NADPH, nicotinamide adenine dinucleotide phosphate.




SFor every 1 NADPH reduced, 2 superoxide molecules are
created. All Nox isoforms have a core catalytic unit and
several core regulatory units, which include 2 organizer
subunits (p47phox and Noxo1), 2 activator subunits
(p67phox and Noxa1), and p22phox and p40phox.1,2
Nox1 is found abundantly in SMCs and in colonic
epithelium, endothelium, fibroblasts, cardiomyocytes, and
microglia.1 It requires the regulatory unit p47phox for its
activity, in addition to other units including p22phox and
p67phox. Studies demonstrate that Nox1 may represent a
common mechanism linking various risk factors with
VSMC dysfunction. Key mechanical and biochemical
mediators of VSMC activation, such as angiotensin II,
aldosterone, platelet-derived growth factor, epidermal
growth factor, and altered mechanical/shear stress, have
been shown to upregulate Nox1 and induce oxidative stress
in VSMCs.1,15,16 Additional studies have implicated
Nox1 as a critical regulator of VSMC migration,
proliferation, and phenotypic modulation, and Nox1
expression is increased in various cardiovascular disease1952 The Journal of Thoracic and Cardiovascular Surstates, including hypertension, atherosclerosis, diabetes,
and hypercholesterolemia.1,17-19 Angiotensin II, a key
mediator of vascular diseases, has been demonstrated to
transduce its pressor and proinflammatory effects, in part
through Nox1.20 Several key transcription factors are upre-
gulated by Nox-derived ROS including G protein–coupled
receptor, Notch, Wnt-b-catenin, MAPK, Janus kinase/
signal transducers and activators of transcription, nuclear
factor kappa B, phosphoinositide-3-kinase/protein kinase
B, hypoxia-inducible factor 1-alpha, activator protein-1,
Rho kinase, and protein tyrosine phosphatases.
The BRCA1 gene is classified as a tumor suppressor
and caretaker because of its proposed genome integrity
maintenance functions.8,9 Germ-line mutations in BRCA1
predominantly predispose carriers to breast and ovarian
cancer in addition to other cancer syndromes.21 BRCA1 is
important for various cellular functions and exerts its effects
on key cellular processes involved in DNA nucleotide
excision and DSB repair, transcriptional regulation,
ubiquitination, and cell cycle control.8,9 Mice harboringgery c June 2014
FIGURE 7. Aortas fromAd-BRCA1–treated SHR rats exhibit less H2A.X phosphorylation than those fromAd-null–treated SHR rats.gH2A.X levels were
assessed via immunohistochemistry. Images are representative of n ¼ 5 per group. *P<.05 versus WKY group; yP<.05 versus Ad-null SHR group.
WKY, Wistar-Kyoto rat; SHR, spontaneously hypertensive rat; Ad-null, control adenovirus; Ad-BRCA1, BRCA1 adenovirus.




Scomplete ablation of BRCA1 die embryonically and
display neuroepithelial, proliferative, and morphogenetic
abnormalities. The BRCA1 gene is composed of 24
exons.22,23 Exon 11 is the largest exon and covers 60%
of the entire BRCA1 gene.21 The exon 11–encoded domain
interacts and colocalizes with RAD51 at the sites of DNA
damage to activate RAD51-mediated repair of DSBs.21,24
Mice with systemic deletion of exon 11 in the BRCA1
gene show recessive embryonic lethality as a result of
impaired DNA damage-induced activation of BRCA1, a
compromised RAD51-dependent repair pathway, and
increased susceptibility to oxidative stress and apoptosis.25
Unopposed activation of ROS eventually leads to DNA
damage, which is the common mechanism through which
cellular apoptosis and/or necrosis develop. Because
BRCA1 is widely known for its effects in promoting
DNA damage repair, particularly in cancer cells, we
reasoned that it may also be an important cellular defense
mechanism against oxidative stress in VSMCs. Our
observations point toward an important and reciprocal
relationship between BRCA1 and oxidative stress in
VSMCs. Under basal conditions, increasing concentrations
of H2O2, a prototypical inducer of oxidative stress, inhibited
BRCA1 expression. Forced overexpression of BRCA1
in vitro upregulated NADPH oxidase Nox1 and its
regulatory subunit p47phox, and inhibited H2O2-induced
ROS production. To confirm the translational significanceThe Journal of Thoracic and Carof these data, we used intravenous adenoviral delivery of
BRCA1 to overexpress BRCA1 systemically in SHR rats,
an established model of hypertension, wherein altered
NADPH-related increases in ROS have been suggested to
be causally related to the development of high blood
pressure. In addition to a reduction in aortic VSMCs
Nox1 and p47phox expression and diminished ROS
generation, systemic BRCA1 therapy not only prevented
an increase in gH2A.X levels and increased RAD51 foci
formation in SHR rat aortas but also attenuated systolic
and diastolic blood pressure in these animals, with an effect
that was noticed early, and was sustained over the 4-week
observation period.
The limitations of this study must be highlighted.
Increased ROS generation is only 1 mechanism of
hypertension development in SHR rats, and other potential
mechanisms such as sympathetic stimulation, alterations in
renal regulatory pathways, or endothelial dysfunction were
not evaluated. Because systemic administration was not
SMC specific, an alternative antihypertensive mechanism
cannot be ruled out. Previous studies have demonstrated a
beneficial effect of BRCA1 on endothelial function,11 and
hence the combined effects on both endothelial and
VSMC pathways may be operative. There was no change
in heart rate, suggesting that the reduction in blood pressure
was not secondary to a negative chronotropic effect.
Although we assessed the translational significance of ourdiovascular Surgery c Volume 147, Number 6 1953
FIGURE 8. Aortas from Ad-BRCA1–treated SHR rats exhibit more RAD51 foci formation than those from Ad-null–treated SHR rats. RAD51 foci were
quantified via immunohistochemistry. Images are representative of n ¼ 5 per group. *P<.05 versus WKY group; yP<.05 versus Ad-null SHR group.
WKY, Wistar-Kyoto rat; SHR, spontaneously hypertensive rat; Ad-null, control adenovirus; Ad-BRCA1, BRCA1 adenovirus.




Sin vitro findings in a model of experimental hypertension,
we appreciate that VSMC may play a role in many diverse
diseases including restenosis, neointimal injury, and
aneurysm formation. Studies using BRCA1-based cell or
gene therapy in such settings may be considered.26-29
The authors thank Praphulla C. Shukla for assistance with the
tail vein injections.
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FIGURE E1. H2O2 reduces HASMC BRCA1 expression in a
concentration-dependent manner. HASMCs were incubated with
increasing concentrations of H2O2 for 24 hours before being processed
for qPCR analysis. n ¼ 5 per group. *P<.05 versus group not exposed
to H2O2. BRCA1, Breast cancer 1, early onset gene; GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase.
FIGUREE2. BRCA1 is overexpressed in SHRRASMCs transfected with
Ad-BRCA1. BRCA1 transcripts in adenovirus-transfected (10 MOI) SHR
RASMCs were evaluated by qPCR. n ¼ 5 per group. *P< .05 versus
Ad-null group. BRCA1, Breast cancer 1, early onset gene; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; Ad-null, control adenovirus;
Ad-BRCA1, BRCA1 adenovirus.
FIGUREE3. BRCA1 is overexpressed in the livers and aortas of SHR rats
after treatment with Ad-BRCA1. SHR rats were administered either
Ad-null or Ad-BRCA1 (53 1010 IU/rat, intravenously). A, Representative
agarose gel images of BRCA1 PCR products of livers from SHR rats 1
week after adenovirus administration. n ¼ 7 per group. Solid line
demarcates nonadjacent lanes from the same gel. B, qPCR results for
BRCA1 transcripts in aortas from SHR rats 4 weeks after adenovirus
administration. n ¼ 7 per group. *P<.05 versus Ad-null. MW, Molecular
weight marker; BRCA1, Breast cancer 1, early onset gene; Ad-null, control
adenovirus; Ad-BRCA1, BRCA1 adenovirus; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; WKY, Wistar-Kyoto rat; SHR, spontaneously
hypertensive rat.
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